CINCINNATI--(BUSINESS WIRE)--Feb. 18, 2014--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), announces that it has entered the
rapidly growing Epigenetics field, with the launch of the first kits in
the new EPIK™ product range; EPIK™ Fast Quantification Kit and EPIK™
These EPIKTM Kits have been developed to meet the needs of
researchers employing PCR and real-time PCR analysis in Epigenetics, by
delivering significantly increased reliability and sensitivity.
Currently the majority of techniques used in Epigenetics have been found
to be unreliable and not reproducible. Methylation of DNA is one of the
best-studied epigenetic phenomena with bisulfite-modification of DNA
considered to be the best method to study DNA methylation patterns. The
EPIK™ Kits are based on the highly sensitive, and customer proven,
MyTaq™ and SensiFAST™ polymerases together with a novel EPIKORE™ buffer
system, formulated to overcome the challenges associated with
bisulfite-modified DNA templates. The high-speed, enhanced specificity
and outstanding reliability of the EPIK™ Kits makes them perfectly
suited to high-throughput epigenetic analysis.
Marco Calzavara, President of Bioline, said, “Epigenetic changes alter
the physical structure of DNA and can turn genes on or off. Strong links
have been identified between Epigenetics, aging and cancer; consequently
there is a lot of active research in this rapidly growing field. Our
customers have told us that reliability is a major issue in Epigenetic
analysis, and with the launch of these new kits, we will bring new
levels of reproducibility and sensitivity to this field.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We
are delighted with the launch of this new product range. Researchers
world-wide will now have greater confidence in their results, as they
push the boundaries of Epigenetics understanding. The EPIKTM
range is a further demonstration of our commitment to our life science
customers and to bringing innovation and quality products to the
research laboratory, clinical diagnostic laboratories, and biotechnology
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
diagnostics manufacturers and biotech companies in more than 60
countries around the world. The Company’s shares are traded on NASDAQ’s
Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com.
more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com.
more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com.
L. Eberly, email@example.com
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700